Compare CNSY & EPOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNSY | EPOW |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 24.2M |
| IPO Year | 2016 | 2019 |
| Metric | CNSY | EPOW |
|---|---|---|
| Price | $1.31 | $4.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $27.75 | N/A |
| AVG Volume (30 Days) | ★ 77.3K | 25.5K |
| Earning Date | 11-17-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,213,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $414.61 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.49 | $0.26 |
| 52 Week High | $4.03 | $7.66 |
| Indicator | CNSY | EPOW |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 55.13 |
| Support Level | $1.52 | $0.55 |
| Resistance Level | $2.28 | $7.66 |
| Average True Range (ATR) | 0.16 | 0.46 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 66.67 | 54.32 |
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.
E Power Inc, through its subsidiaries, is engaged in the manufacturing and sale of graphite anode material for lithium-ion batteries. It operates a plant in Guizhou Province, China, powered by electricity from renewable sources, which contributes to the plant's low production costs and reduced environmental impact in the production of graphite anode materials. Additionally, the Group also operates a knowledge-sharing platform business. Its reportable operating segments are: Graphite anode business, which generates the maximum revenue, and Knowledge sharing and enterprise business. Substantially all of the Group's revenue is derived in the People's Republic of China (the PRC).